Peppermint Venture Partners GmbH

Labforward supports laboratory teams on their quest for groundbreaking discoveries and delivering innovative high-quality products. With digital tools for laboratories, it increases productivity and improves efficiency in laboratories. The company's products include the user-friendly electronic laboratory notebook (ELN) Labfolder and the Internet-of-Things (IoT) platform Laboperator. The digital connectivity of laboratories and innovative data management is a focus topic in industry and research. In a fragmented landscape of high-tech equipment and specialized software, Labforward links data silos and helps to eliminate costly and error-prone data transfers. Based on this horizontal connectivity, the software Laboperator enables the remote control and monitoring of laboratory equipment, the integration of LIMS systems, databases and special software as well as the automation of workflows. The Labfolder data platform aggregates both automatically recorded and manually added data and enables the review, sharing, retrieval and validation of data by means of a collaborative ELN. Whether life sciences, chemical synthesis, analytics, quality control or research and development: no matter how specific the field or task of a laboratory may be, the way it works and the requirements for data management have a common core. Labforward focuses on this core.

CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intends to extend the benefits of cryoenergy to the problem of diseased coronary arteries.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, specializing in innovative solutions for the treatment and management of glaucoma. Founded in 2010, the company has developed the Eyemate system, which features an implantable micro sensor designed for continuous intraocular pressure measurement. This technology aims to enhance the monitoring and therapy of glaucoma patients, providing eye care specialists with proactive and personalized guidance in treatment. By integrating advanced medical technology with information systems, Implandata addresses an underserved area in glaucoma care, facilitating more effective management for patients, their families, and healthcare providers.

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intends to extend the benefits of cryoenergy to the problem of diseased coronary arteries.

Emperra GmbH E-Health Technologies, founded in 2008 and based in Potsdam, Germany, specializes in the development of telemedical products aimed at managing diabetes. The company focuses on GSM and web-based solutions that facilitate the tracking, monitoring, and transmission of crucial diagnostic and therapeutic data for diabetic patients, including insulin doses, blood sugar levels, and carbohydrate intake. Emperra's innovative diabetes monitoring system integrates a Bluetooth-enabled insulin pen and a wireless blood glucose meter, allowing healthcare professionals to effectively monitor their patients' conditions and adjust treatments as necessary.

Cevec Pharmaceuticals GmbH specializes in the production of biopharmaceutical molecules characterized by human glycosylation patterns. The company focuses on developing therapeutic proteins and monoclonal antibodies using its proprietary CAP-GO platform, which enables the creation of optimized expression vectors and the generation of serum-free cell lines for recombinant protein production. Additionally, Cevec utilizes the CAP-GT platform for large-scale production of gene therapy vectors, including lentiviral, adenoviral, and AAV types. By leveraging a human cell-based expression system, Cevec addresses the challenges of producing complex glycosylated proteins that are difficult to express in traditional cell lines. The company also offers contract manufacturing services to meet diverse client needs. Founded in 2001 and based in Cologne, Germany, Cevec has established a strategic collaboration with BioLamina AB to enhance its capabilities in the biopharmaceutical sector.

Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, specializing in innovative solutions for the treatment and management of glaucoma. Founded in 2010, the company has developed the Eyemate system, which features an implantable micro sensor designed for continuous intraocular pressure measurement. This technology aims to enhance the monitoring and therapy of glaucoma patients, providing eye care specialists with proactive and personalized guidance in treatment. By integrating advanced medical technology with information systems, Implandata addresses an underserved area in glaucoma care, facilitating more effective management for patients, their families, and healthcare providers.

CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intends to extend the benefits of cryoenergy to the problem of diseased coronary arteries.

CAP-CMV GmbH develops vaccines for protection against human Cytomegalovirus (HCMV) infection.

CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intends to extend the benefits of cryoenergy to the problem of diseased coronary arteries.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, specializing in innovative solutions for the treatment and management of glaucoma. Founded in 2010, the company has developed the Eyemate system, which features an implantable micro sensor designed for continuous intraocular pressure measurement. This technology aims to enhance the monitoring and therapy of glaucoma patients, providing eye care specialists with proactive and personalized guidance in treatment. By integrating advanced medical technology with information systems, Implandata addresses an underserved area in glaucoma care, facilitating more effective management for patients, their families, and healthcare providers.

As of May 13, 2005, weblicon technologies AG was acquired by Synchronica Software GmbH. Weblicon technologies AG is based in Berlin, Germany and develops and markets web-based applications such as online organizer, featuring online calendaring, contact management and e-mail. The company’s product can be integrated into existing networks of servers, applications and databases and is platform-independent and customizable. Major clients are telecommunication companies, portals as well as service providers.